High serglycin levels are present in bone marrow aspirates of >30% of newly diagnosed multiple myeloma patients, and are required for adhesion, in vivo growth, and vascularization of multiple myeloma cell (73, 74). Here, SRGN is linked to plasma cell myeloma.